Neratinib, a pan ERBB/HER inhibitor, restores sensitivity of PTEN-null, BRAFV600E melanoma to BRAF/MEK inhibition

IntroductionApproximately 50% of melanomas harbor an activating BRAFV600E mutation. Standard of care involves a combination of inhibitors targeting mutant BRAF and MEK1/2, the substrate for BRAF in the MAPK pathway. PTEN loss-of-function mutations occur in ~40% of BRAFV600E melanomas, resulting in i...

Descripció completa

Dades bibliogràfiques

Autors principals:	Evan DuBose, Samantha M. Bevill, Dana K. Mitchell, Noah Sciaky, Brian T. Golitz, Shelley A. H. Dixon, Steven D. Rhodes, James E. Bear, Gary L. Johnson, Steven P. Angus
Format:	Artigo
Idioma:	Inglês
Publicat:	Frontiers Media S.A. 2024-05-01
Col·lecció:	Frontiers in Oncology
Matèries:	melanoma kinase inhibitor drug synergy ERBB3 resistance
Accés en línia:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1191217/full
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!